BLAU3Blau Farmacêutica S.A.Company Data · 2T26updated 2026-08-24
1
Overview
4T17 — 2T26 · 35 quarters
▼
Blau Farmacêutica S.A.
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics products. Blau Farmacêutica S.A. was incorporated in 1987 and is headquartered in Cotia, Brazil.
SectorFarmacêutico e Higiene
Company HeadquartersCotia, SP
Full Time Employees—
CEOMr. Marcelo Rodolfo Hahn
Listing SegmentNovo Mercado
Foundation1987
Customer Rating—
Employee Rating—
Estrutura Acionária
18%Free Float
Marcelo Rodolfo Hahn82%
Free Float18%
Valuation
| Price | R$ 8,96 |
| Shares Outstanding | 228.758 |
| Market Capitalization | 2.050 |
| ( - ) Cash & Equivalents | 885 |
| ( + ) Total Debt | 853 |
| ( = ) Enterprise Value | 2.018 |
| P/E | 8,7x |
| EV / EBITDA | 5,2x |
R$ 8,96
Adj close · daily
Income Statement
| Revenue | 1.786 |
| EBITDA | 386 |
| EBIT | 309 |
| Net Income | 235 |
| SG&A % | (21,6%) |
Balance Sheet
| Assets | 4.027 |
| Cash | 885 |
| Total Debt | 853 |
| Net Debt | (32) |
| Fixed Assets | 1.563 |
| Working Capital | 852 |
| Equity | 2.316 |
Invested Capital & Reinvestment
| Invested Capital Turnover | 0,74x |
| Marginal IC Turnover | (0,49x) |
| Reinvestment % NOPAT | 112,7% |
| Working Capital Turnover | 1,92x |
| Cash Conv. Cycle | 251,9 |
| Fixed Assets Turnover | 1,21x |
| D&A % Fixed Assets | 5,3% |
| Capex % Revenue | 21,8% |
10,1 %
RoIC · LTM
RoIC (LTM)
Margins & Returns
| Revenue Growth | 1,1% |
| Gross Margin | 41,3% |
| EBITDA Margin | 21,6% |
| Net Income Margin | 13,1% |
| Effective Tax Rate | 21,8% |
| Operating Leverage | (25,38x) |
| RoIC | 10,1% |
| RoE | 10,2% |
Capital Structure
| Current Ratio | 3,23x |
| Financial Leverage | 1,74x |
| Asset Turnover | 0,48x |
| Net Debt / EBITDA | (0,08x) |
| Net Debt & Lease / EBITDA | 0,00x |
Cash Flow
| CFO Conversion | 110,0% |
| FCFF Yield | 1,5% |
| FCFE Yield | 15,8% |
| Payout Ratio | 34,1% |
| Dividend Yield | 3,3% |
| Interest % FCFF | 0,0% |
Latest CVM filings
- 2026-08-12reported 2T26
- 2026-05-07reported 1T26
- 2026-03-17reported 4T25
- 2025-11-04reported 3T25
- 2025-08-05reported 2T25
- 2025-05-06reported 1T25